Interview: Nobel chemistry laureate Jennifer Doudna on the promise and peril of the genetic editing revolution
By John Mecklin,
Bulletin of the Atomic Scientists
| 12. 07. 2020
Just weeks after I interviewed her this September, UC Berkeley professor Jennifer Doudna and her colleague Emmanuelle Charpentier were jointly awarded the Nobel Prize in Chemistry for their discovery of the CRISPR/Cas9 genetic editing tool. An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR sequences were found in bacteria, where they protect against viruses by chopping them into pieces. Doudna and Charpentier devised a way to reprogram these genetic scissors, so they could be directed to cut any DNA molecule at a predetermined site.
The CRISPR/Cas9 editing tool has greatly reduced the amount of time needed to edit genes and is now in use by researchers around the world. “There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments,” Claes Gustafsson, chair of the Nobel Committee for Chemistry, said in a press release accompanying the Nobel Prize announcement.
The positive potential of CRISPR editing tools is indeed breathtaking. “This tool has contributed to many important discoveries...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...